Virbac


2022 ended on a high note but soft 2023 guidance maintained

20/01/23 -"Q4 22 sales exceeded expectations and both segments contributed healthily, with CA being the dominant growth engine. FPA however was somewhat restrained by external factors. While the 2022 margin is ..."

Pages
61
Language
English
Published on
20/01/23
You may also be interested by these reports :
02/02/23
Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In ...

02/02/23
Appreciating aprocitentan – How the royalty deal might look like – TP raised to CHF 18.20 (from 15.90) / Add reiterated

02/02/23
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and ...

31/01/23
We have integrated the first set of the 2022 figures. The significantly higher EPS stems mainly from the cancellation of the anticipated CHF-900m ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO